Fingolimod for the treatment of relapsing multiple sclerosis

References

• Anderson DW, Ellenberg JH, Leventhal CM et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann. Neurol.31(3), 333–336 (1992).
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med.343(13), 938–952 (2000).
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain112(Pt 1), 133–146 (1989).
   PubMed Web of Science ®Google Scholar
• Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology61(11), 1528–1532 (2003).
   PubMed Web of Science ®Google Scholar
• Bejaoui K, Rolak LA. What is the risk of permanent disability from a multiple sclerosis relapse? Neurology74(11), 900–902 (2010).
   PubMedGoogle Scholar
• Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci.31, 247–269 (2008).
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Degenhardt A et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain133(Pt 7), 1914–1929 (2010).
   PubMed Web of Science ®Google Scholar
• Kappos L, Traboulsee A, Constantinescu C et al. Long-term subcutaneous interferon β-1a therapy in patients with relapsing–remitting MS. Neurology67(6), 944–953 (2006).
   PubMed Web of Science ®Google Scholar
• Avonex® (interferon β-1a) IM Injection. Prescribing Information. Biogen Idec Inc., Cambridge, MA, USA (2008).
   Google Scholar
• Novantrone (mitoxantrone) Injection. Prescribing Information. EMD Serono, Inc., Rockland, MA, USA (2010).
   Google Scholar
• Betaseron® (interferon β-1a) SC Injection. Prescribing Information. Bayer HealthCare Pharmaceuticals Inc., Montville, NJ, USA (2009).
   Google Scholar
• Extavia® (interferon β-1b). Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (2009).
   Google Scholar
• Copaxone® (glatiramer acetate) Injection. Prescribing Information. Teva Neuroscience, Inc., Kansas City, MO, USA (2009).
   Google Scholar
• Río J, Montalban X. Interferon-β1b in the treatment of multiple sclerosis. Expert Opin. Pharmacother.6(16), 2877–2886 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 402–415 (2010).
   PubMed Web of Science ®Google Scholar
• Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing–remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs70(12), 1545–1577 (2010).
   PubMed Web of Science ®Google Scholar
• Interferon β-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology43(4), 655–661 (1993).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol.39(3), 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology45(7), 1268–1276 (1995).
   PubMed Web of Science ®Google Scholar
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet352(9139), 1498–1504 (1998).
   PubMed Web of Science ®Google Scholar
• Stone LA, Frank JA, Albert PS et al. Characterization of MRI response to treatment with interferon β-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology49(3), 862–869 (1997).
   PubMed Web of Science ®Google Scholar
• Panitch H, Miller A, Paty D, Weinshenker B. Interferon β-1b in secondary progressive MS: results from a 3-year controlled study. Neurology63(10), 1788–1795 (2004).
   PubMed Web of Science ®Google Scholar
• Ford C, Goodman AD, Johnson K et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult. Scler.16(3), 342–350 (2010).
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Reder AT, Filippi M et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology71(2), 136–144 (2008).
   PubMed Web of Science ®Google Scholar
• Treadaway K, Cutter G, Salter A et al. Factors that influence adherence with disease-modifying therapy in MS. J. Neurol.256(4), 568–576 (2009).
   PubMed Web of Science ®Google Scholar
• Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L. Adherence to interferon-β treatment and results of therapy switching. J. Neurol. Sci.259(1–2), 104–108 (2007).
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet360(9350), 2018–2025 (2002).
   PubMed Web of Science ®Google Scholar
• Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology74(18), 1463–1470 (2010).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev. Neurother.4(4), 571–580 (2004).
   PubMedGoogle Scholar
• Goodin DS, Cohen BA, O’Connor P, Kappos L, Stevens JC. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology71(10), 766–773 (2008).
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med.362(5), 387–401 (2010).
   PubMed Web of Science ®Google Scholar
• Spiegel S, Milstien S. Sphingolipid metabolites: members of a new class of lipid second messengers. J. Membr. Biol.146(3), 225–237 (1995).
   PubMed Web of Science ®Google Scholar
• Spiegel S, Cuvillier O, Edsall LC et al. Sphingosine-1-phosphate in cell growth and cell death. Ann. N. Y. Acad. Sci.845, 11–18 (1998).
   PubMed Web of Science ®Google Scholar
• Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol. Res.47(5), 401–407 (2003).
   PubMed Web of Science ®Google Scholar
• Lee MJ, Van Brocklyn JR, Thangada S et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science279(5356), 1552–1555 (1998).
   PubMed Web of Science ®Google Scholar
• Lee HY, Shin EH, Bae YS. Sphingosylphosphorylcholine stimulates human monocyte-derived dendritic cell chemotaxis. Acta Pharmacol. Sin.27(10), 1359–1366 (2006).
   PubMedGoogle Scholar
• Allende ML, Yamashita T, Proia RL. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood102(10), 3665–3667 (2003).
   PubMed Web of Science ®Google Scholar
• Mizugishi K, Yamashita T, Olivera A et al. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell Biol.25(24), 11113–11121 (2005).
   PubMed Web of Science ®Google Scholar
• Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem.73, 321–354 (2004).
   PubMed Web of Science ®Google Scholar
• Mandala S, Hajdu R, Bergstrom J et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science296(5566), 346–349 (2002).
   PubMed Web of Science ®Google Scholar
• Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J. Cell Biochem.92(5), 913–922 (2004).
   PubMed Web of Science ®Google Scholar
• Watterson K, Sankala H, Milstien S, Spiegel S. Pleiotropic actions of sphingosine-1-phosphate. Prog. Lipid Res.42(4), 344–357 (2003).
   PubMedGoogle Scholar
• Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol.33(2), 91–101 (2010).
   PubMed Web of Science ®Google Scholar
• Chiba K, Yanagawa Y, Masubuchi Y et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol.160(10), 5037–5044 (1998).
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo CG, Cinamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature427(6972), 355–360 (2004).
   PubMed Web of Science ®Google Scholar
• Yanagawa Y, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer’s patches by FTY720-induced lymphocyte homing. Immunology95(4), 591–594 (1998).
   PubMed Web of Science ®Google Scholar
• Gräler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J.18(3), 551–553 (2004).
   PubMed Web of Science ®Google Scholar
• Mehling M, Lindberg RL, Kuhle J et al. Oral fingolimod (FTY720) treatment reduces peripheral IL-17-producing TH17 cells in patients with multiple sclerosis. Mult. Scler.14(1 Suppl.), S234(Abstract P697) (2008).
   Web of Science ®Google Scholar
• Tzartos JS, Friese MA, Craner MJ et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol.172(1), 146–155 (2008).
   PubMed Web of Science ®Google Scholar
• Kebir H, Kreymborg K, Ifergan I et al. Human TH17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation. Nat. Med.13(10), 1173–1175 (2007).
   PubMed Web of Science ®Google Scholar
• Mehling M, Lindberg R, Raulf F et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology75(5), 403–410 (2010).
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Metzler B, Matloubian H. The mode of action of fingolimod (FTY720), an oral sphingosine 1-phosphate receptor modulator that is highly effective in human multiple slcerosis (Phase II). Mult. Scler.12, S100(Abstract P374) (2006).
   Google Scholar
• Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant.4(7), 1019–1025 (2004).
   PubMed Web of Science ®Google Scholar
• Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat. Immunol.8(12), 1295–1301 (2007).
   PubMed Web of Science ®Google Scholar
• Pinschewer DD, Ochsenbein AF, Odermatt B et al. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol.164(11), 5761–5770 (2000).
   PubMed Web of Science ®Google Scholar
• Hofmann M, Brinkmann V, Zerwes HG. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int. Immunopharmacol.6(13–14), 1902–1910 (2006).
   PubMed Web of Science ®Google Scholar
• Schmouder R, Aradhye S, O’Connor P, Kappos L. Pharmacodynamic effects of oral fingolimod (FTY72). Mult. Scler.12(Suppl. 1), S101–S102 (Abstract P378) (2006).
   PubMedGoogle Scholar
• Westermann J, Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin. Investig.70(7), 539–544 (1992).
   PubMedGoogle Scholar
• Johnson TA, Shames I, Keezer M et al. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clin. Immunol.137(1), 15–20 (2010).
   PubMed Web of Science ®Google Scholar
• Jung CG, Kim HJ, Miron VE et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia55(16), 1656–1667 (2007).
   PubMed Web of Science ®Google Scholar
• Gardell S, Choi JW, Herr D et al. Evidence for neural S1P receptor signaling in EAE and FTY720 efficacy. Mult. Scler.13(2 Suppl.), S70(Abstract P243) (2007).
   Google Scholar
• Saini HS, Coelho RP, Goparaju SK et al. Novel role of sphingosine kinase 1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors. J. Neurochem.95(5), 1298–1310 (2005).
   PubMed Web of Science ®Google Scholar
• Novgorodov AS, El Alwani M, Bielawski J, Obeid LM, Gudz TI. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J.21(7), 1503–1514 (2007).
   PubMed Web of Science ®Google Scholar
• Miron VE, Jung CG, Kim HJ et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann. Neurol.63(1), 61–71 (2008).
   PubMed Web of Science ®Google Scholar
• Barske C, Osinde M, Mir AK et al. FTY720 (fingolimod) enhances the number of immature and mature oligodendrocytes. Mult. Scler.13(2 Suppl.), S148(Abstract P498) (2007).
   Google Scholar
• Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J. Pharmacol. Exp. Ther.323(2), 626–635 (2007).
   PubMed Web of Science ®Google Scholar
• Toman RE, Payne SG, Watterson KR et al. Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J. Cell Biol.166(3), 381–392 (2004).
   PubMed Web of Science ®Google Scholar
• Kimura A, Ohmori T, Ohkawa R et al. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells25(1), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Edsall LC, Pirianov GG, Spiegel S. Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation. J. Neurosci.17(18), 6952–6960 (1997).
   PubMed Web of Science ®Google Scholar
• Chin TY, Hwang HM, Chueh SH. Distinct effects of different calcium-mobilizing agents on cell death in NG108-15 neuroblastoma X glioma cells. Mol. Pharmacol.61(3), 486–494 (2002).
   PubMedGoogle Scholar
• Shinpo K, Kikuchi S, Moriwaka F, Tashiro K. Protective effects of the TNF-ceramide pathway against glutamate neurotoxicity on cultured mesencephalic neurons. Brain Res.819(1–2), 170–173 (1999).
   PubMed Web of Science ®Google Scholar
• Deogracias R, Klein C, Matsumoto T et al. Expression of brain-derived neurotrophic factor is regulated by fingolimod (FTY720) in cultured neurons. Mult. Scler.14(1 Suppl.), S243(Abstract P728) (2008).
   PubMedGoogle Scholar
• Balatoni B, Storch MK, Swoboda EM et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res. Bull.74(5), 307–316 (2007).
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Al-Izki S, Pryce G, Jackson S, Baker D. Control of chronic relapsing progressive EAE with fingolimod. Presented at: 60th Annual Meeting of the American Academy of Neurology, Chicago, IL, USA, April 12–17, 2008 (Poster presentation).
   Google Scholar
• Rao TS, Lariosa-Willingham KD, Lin FF et al. Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes. Brain Res.990(1–2), 182–194 (2003).
   PubMed Web of Science ®Google Scholar
• Rao TS, Lariosa-Willingham KD, Lin FF et al. Growth factor pre-treatment differentially regulates phosphoinositide turnover downstream of lysophospholipid receptor and metabotropic glutamate receptors in cultured rat cerebrocortical astrocytes. Int. J. Dev. Neurosci.22(3), 131–135 (2004).
   PubMed Web of Science ®Google Scholar
• Mullershausen F, Craveiro LM, Shin Y et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem102(4), 1151–1161 (2007).
   PubMed Web of Science ®Google Scholar
• Yamagata K, Tagami M, Torii Y et al. Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia41(2), 199–206 (2003).
   PubMed Web of Science ®Google Scholar
• Osinde M, Mullershausen F, Dev KK. Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology52(5), 1210–1218 (2007).
   PubMedGoogle Scholar
• Rouach N, Pébay A, Même W et al. S1P inhibits gap junctions in astrocytes: involvement of Gi and Rho GTPase/ROCK. Eur. J. Neurosci.23(6), 1453–1464 (2006).
   PubMed Web of Science ®Google Scholar
• Choi JW, Herr D, Kennedy G, Chun J. Astrocytic sphingosine 1-phosphate (S1P) receptor subtype 1 signalling influences levels of S1P and cytokines during experimental autoimmune encephalomyelitis and fingolimod (FTY720) intervention. Mult. Scler.15, S58(Abstract P227) (2009).
   Google Scholar
• Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med.355(11), 1124–1140 (2006).
   PubMed Web of Science ®Google Scholar
• O’Connor P, Comi G, Montalban X et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a Phase II extension study. Neurology72(1), 73–79 (2009).
   PubMed Web of Science ®Google Scholar
• Comi G, O’Connor P, Montalban X et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult. Scler.16(2), 197–207 (2010).
   PubMed Web of Science ®Google Scholar
• Tysabri (natalizumab) Injection. Prescribing Information. Biogen Idec Inc., Cambridge, MA, USA (2008).
   Google Scholar
• Neutralizing antibodies during treatment of multiple sclerosis with interferon β-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology47(4), 889–894 (1996).
   PubMed Web of Science ®Google Scholar
• PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Neurology56(12), 1628–1636 (2001).
   PubMed Web of Science ®Google Scholar
• Francis GS, Rice GP, Alsop JC. Interferon β-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology65(1), 48–55 (2005).
   PubMed Web of Science ®Google Scholar
• Pachner AR, Warth JD, Pace A, Goelz S. Effect of neutralizing antibodies on biomarker responses to interferon β: the INSIGHT study. Neurology73(18), 1493–1500 (2009).
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Giovannoni G, Confavreux C et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology69(14), 1391–1403 (2007).
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Barbarash O, Casset-Semanaz F et al. Safety and immunogenicity of a new formulation of interferon β-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult. Scler.15(2), 219–228 (2009).
   PubMed Web of Science ®Google Scholar
• Foster CA, Howard LM, Schweitzer A et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J. Pharmacol. Exp. Ther.323(2), 469–475 (2007).
   PubMed Web of Science ®Google Scholar
• Gilenya™ (fingolimod) Capsules for Oral Use. Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (2010).
   Google Scholar
• The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, USA (2006).
   Google Scholar
• Uhlig S, Gulbins E. Sphingolipids in the lungs. Am. J. Respir. Crit. Care Med.178(11), 1100–1114 (2008).
   PubMedGoogle Scholar
• Salvadori M, Budde K, Charpentier B et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am. J. Transplant.6(12), 2912–2921 (2006).
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H, Pescovitz MD, Cibrik D et al. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation82(12), 1689–1697 (2006).
   PubMed Web of Science ®Google Scholar
• Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther.115(1), 84–105 (2007).
   PubMed Web of Science ®Google Scholar
• Chen E, Looman M, Laouri M et al. Burden of illness of diabetic macular edema: literature review. Curr. Med. Res. Opin.26(7), 1587–1597 (2010).
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Halkiadakis I, Pantelia E et al. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology111(5), 946–953 (2004).
   PubMed Web of Science ®Google Scholar
• Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon β therapy in relapsing–remitting multiple sclerosis. Eur. Neurol.59(3–4), 131–135 (2008).
   PubMed Web of Science ®Google Scholar